S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
66,000% upside on tiny biotech? (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
66,000% upside on tiny biotech? (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
66,000% upside on tiny biotech? (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
66,000% upside on tiny biotech? (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
66,000% upside on tiny biotech? (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
66,000% upside on tiny biotech? (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
66,000% upside on tiny biotech? (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
66,000% upside on tiny biotech? (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift

AstraZeneca (AZN) Stock Forecast & Price Target

GBX 9,906
-196.00 (-1.94%)
(As of 05:31 AM ET)

AstraZeneca Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings

Analysts' Consensus Price Target

£119
High Forecast£135
Average Forecast£119
Low ForecastGBX 9,900
TypeCurrent Forecast
2/22/23 to 2/22/24
1 Month Ago
1/23/23 to 1/23/24
3 Months Ago
11/24/22 to 11/24/23
1 Year Ago
2/22/22 to 2/22/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target£119£118.95£117.25£118.94
Get AstraZeneca Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

AZN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaMedical Companies
Consensus Rating Score
2.60
2.68
Consensus RatingModerate BuyModerate Buy
News Sentiment RatingNeutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight£125+22.50%
2/16/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold£110+10.29%
2/12/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
2/12/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSell£107 ➝ GBX 9,900+4.16%
2/8/2024Shore Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
11/28/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
11/21/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy£125+23.79%
11/20/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy£135+33.66%
10/3/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
9/25/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target£127 ➝ £129+15.72%
4/11/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target£127 ➝ £119+2.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:07 AM ET.












AZN Price Target - Frequently Asked Questions

What is AstraZeneca's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for AstraZeneca stock is Moderate Buy based on the current 1 sell rating, 2 hold ratings and 7 buy ratings for AZN. The average twelve-month price prediction for AstraZeneca is £119 with a high price target of £135 and a low price target of GBX 9,900. Learn more on AZN's analyst rating history.

Do Wall Street analysts like AstraZeneca more than its competitors?

Analysts like AstraZeneca less than other Medical companies. The consensus rating score for AstraZeneca is 2.60 while the average consensus rating score for medical companies is 2.68. Learn more on how AZN compares to other companies.

Does AstraZeneca's stock price have much upside?

According to analysts, AstraZeneca's stock has a predicted upside of 16.07% based on their 12-month stock forecasts.

What analysts cover AstraZeneca?

AstraZeneca has been rated by BMO Capital Markets, Citigroup, Jefferies Financial Group, JPMorgan Chase & Co., Shore Capital, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (LON:AZN) was last updated on 2/22/2024 by MarketBeat.com Staff

From Our Partners
pixelpixel